FDA Urged Reformation of PMTA Process

Regulations by 2FIRSTS.ai
Dec.18.2023
FDA Urged Reformation of PMTA Process
US senators urge the FDA's Center for Tobacco Products to reform the pre-market tobacco product application process.

According to a report from Vaporvoice, United States Senators Joe Manchin, Rand Paul, and Ted Budd have jointly written a letter to the Center for Tobacco Products (CTP) of the Food and Drug Administration (FDA), urging it to reform the pre-market tobacco product application (PMTA) process. Additionally, they have requested the center to provide information regarding policies and actions taken to ensure that its actions are grounded in science and evidence and conducted in an effective manner.

 

A report highlights that "smoking is a leading cause of preventable diseases and deaths in the United States, with approximately 31 million Americans being smokers," wrote the senators in their letter. "In order to achieve the Food and Drug Administration's goal of reducing harm, an effective authorization process must be in place.

 

Since 2009, more than 26 million PMTA applications for new products have been submitted in the United States. However, the Center for Tobacco Products (CTP) has only approved less than 50 of these applications. Senators argue that availability of scientifically backed and authorized PMTA or MRTP could potentially improve the health conditions of current smokers using risky tobacco products.

 

Senators mentioned that in order to achieve the goal of preventing harm to public health, the FDA must have an effective authorization process. Additionally, they also stated that the FDA's authorization speed is far from acknowledging the risk levels of tobacco products.

 

Senators wrote in a letter, "Previously, CTP attributed its backlog of work to staff shortage, but over the past decade, the number of employees at CTP has grown from 426 in 2013 to over 1,100 now.

 

According to them, since 2009, the FDA has had the authority to assess and collect user fees from tobacco manufacturers and importers, with these fees reaching $712 million per year since 2019. "With such substantial resources, there should be no reason for the CTP to be incapable of complying with the requirements of the Food, Drug, and Cosmetic Act.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

COP11 Concludes with Major Decisions on Global Tobacco Control
COP11 Concludes with Major Decisions on Global Tobacco Control
The Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on November 22, with 160 Parties adopting major decisions on tobacco and nicotine regulation, environmental protection, sustainable financing, and tobacco industry liability. A landmark decision mandates a complete ban on the use and sale of tobacco and all novel nicotine products across all UN premises worldwide.
Nov.24 by 2FIRSTS.ai
BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
British American Tobacco (BAT) acquires state-owned shares of UZBAT, a joint venture in Uzbekistan, for $22.3 million.
Oct.15 by 2FIRSTS.ai
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.
Nov.26 by 2FIRSTS.ai
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.
Nov.18 by 2FIRSTS.ai
South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine
South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine
South Korea’s amendment to the Tobacco Business Act, which would classify synthetic nicotine vapes and vape liquids as “tobacco” for regulatory and taxation purposes, has been delayed once again. Despite the government stressing its urgency due to youth access and risks of illicit drug mixing, both ruling and opposition parties at the Legislation and Judiciary Committee meeting agreed that the bill requires further discussion.
Nov.13 by 2FIRSTS.ai
2Firsts Observation | U.S. E-cigarette Regulation Enters Normalized Phase as Federal and State Authorities Tighten Compliance Frameworks
2Firsts Observation | U.S. E-cigarette Regulation Enters Normalized Phase as Federal and State Authorities Tighten Compliance Frameworks
In just two months, U.S. authorities seized over 7 million illegal e-cigarettes. 2Firsts’ analysis reveals a shift toward institutionalized regulation, with federal and state agencies intensifying enforcement — signaling a major reset in the world’s largest and most influential vaping market.
Oct.28